Gender Male
Paul Klingenstein has been a venture capital investor for most of his professional career.
Beginning at Warburg Pincus in the early 1980s, he joined Accel Partners in 1986 and helped, through the next decade, to build a leading venture capital firm. After a brief period as an advisor to the Rockefeller Foundation, he formed Aberdare Ventures in
1999.
During this period he has invested in more than 50 companies, the majority of which are now public, or have been merged into public companies.
His current and former boards include Clovis Oncology and Glycomed. He has served on the boards of various educational and non-profit institutions including the African Wildlife Foundation, and the International AIDS Vaccine Initiative.
He received an AB from Harvard and an MBA from Stanford.
